Immune checkpoint inhibitors (ICIs) have greatly improved survival of several cancers with historically very poor prognosis. ICIs act by stimulating the patient's own immune system to fight cancer. Simultaneously, this immune activation can lead to immune-related adverse events (irAEs), including rheumatic manifestations (Rh-irAEs). Rh-irAEs mimic primary rheumatic diseases including arthritis, polymyalgia rheumatica, myositis, vasculitis, sarcoidosis, and sicca. This article summarizes the latest evidence regarding the utility of laboratory investigations in Rh-irAEs.

Ladouceur, A., Ezdoglian, A., Sparks, J. A., Hudson, M., Jamal, S., Clifford, A., Roberts, J., & Ye, C. (2024). The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events. Rheumatic diseases clinics of North America, 50(2), 181–199. https://doi.org/10.1016/j.rdc.2024.01.003